Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Chari A, et al. Among authors: richter j. N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455. N Engl J Med. 2019. PMID: 31433920 Clinical Trial.
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Vogl DT, et al. Among authors: richter j. J Clin Oncol. 2018 Mar 20;36(9):859-866. doi: 10.1200/JCO.2017.75.5207. Epub 2018 Jan 30. J Clin Oncol. 2018. PMID: 29381435 Free PMC article. Clinical Trial.
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.
Barley K, Sanchez L, Cho HJ, Parekh S, Madduri D, Richter J, Isola L, Goldstein T, Dhadwal A, Zarychta K, Sanchez GM, Catamero D, Verina D, Florendo E, Yum MH, La L, Gullie J, Chan E, Jagannath S, Chari A. Barley K, et al. Among authors: richter j. Am J Hematol. 2020 Feb;95(2):E51-E54. doi: 10.1002/ajh.25695. Epub 2019 Dec 22. Am J Hematol. 2020. PMID: 31814152 Free article. Clinical Trial. No abstract available.
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: richter j. Leukemia. 2020 Sep;34(9):2430-2440. doi: 10.1038/s41375-020-0756-6. Epub 2020 Feb 24. Leukemia. 2020. PMID: 32094461 Free PMC article.
3,237 results